Hospital-based registered nurses report that fewer patients are being harmed by medical errors than was the case 10 years ago.
Hospital-based registered nurses report that fewer patients are being harmed by medical errors than was the case 10 years ago, according to a survey published in the November issue of RN magazine.
In a survey of 743 randomly selected nurses, 67% said they were not aware of any patients who had been harmed due to incompetence, physician errors or nurse errors during the month prior to the survey. In 1988, only 59% of nurses said the same.
Furthermore, 78% reported that they knew of no dangerous errors committed by unlicensed assistant personnel during the month preceding the survey.
However, when errors did occur, more nurses said they chose not to report the events to their supervisors.
Twenty-six percent of respondents said they knew of at least one physician error or incompetence that had resulted in harm to a patient, but they did not report it. Another 23% of respondents said they knew of a patient being harmed by a nurse's error but did not report it.
In 1988, the percentage of nurses who failed to report physicians' errors or incompetencies was 22%.
The percentage of nurses who failed to report serious errors made by nurses was 17% in 1988.
Why aren't nurses reporting errors as often as they used to?
Fear of reprimand or dismissal or lack of institutional support are two reasons, according to Marianne Mattera, the magazine's editor. State law does little to protect nurses who "blow the whistle" on physicians or nursing peers. Only Kentucky, Minnesota and New Jersey have laws that protect nurses from retaliation by an employer for reporting care that endangers patients.
RN magazine, a sister publication of Pharmaceutical Representative, has conducted its nursing ethics survey since 1988. PR
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.